• No results found

[PDF] Top 20 Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Has 10000 "Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma" found on our website. Below are the top 20 most common "Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma".

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

... ameliorate daratumumab interference with blood com- patibility testing are being ...denatures CD38, or the addition of neutralizing agents such as anti- idiotype antibodies against daratumumab or ... See full document

8

Potential role of daratumumab in the treatment of multiple myeloma

Potential role of daratumumab in the treatment of multiple myeloma

... of monoclonal antibody therapy in MM remains relatively ...humanized antibody to CD38 that has shown great promise as an effective monoclonal antibody with ADCC, CDC, ADCP, and ... See full document

6

Daratumumab Plus Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of POLLUX

Daratumumab Plus Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of POLLUX

... noted. First, although balanced between treatment arms, only a subset of patient samples was collected for central cytogenetic testing as outlined in the ...future daratumumab studies in ... See full document

9

New developments in the treatment of multiple myeloma – <br />clinical utility of daratumumab

New developments in the treatment of multiple myeloma &ndash; <br />clinical utility of daratumumab

... the first full dose, a washout period of 3 weeks to collect safety and PK data was ...received daratumumab at a dose of 8 mg/kg in eight, once-weekly infusions and then in twice-monthly infusions for 16 ... See full document

13

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date

... the first time, the antitumor efficiency of antibody-based immunotherapy targeting myeloma cells in a large, randomized controlled Phase III ...for treatment of patients with RRMM. For these ... See full document

12

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

... with multiple myeloma has improved tremendously with the advent of bortezomib and immunomodulatory drugs like thalidomide and lenalidomide, the disease remains incurable and patients will eventually be ... See full document

6

Elotuzumab for the treatment of multiple myeloma

Elotuzumab for the treatment of multiple myeloma

... of multiple myeloma (MM) therapy has changed dramatically in the past two ...and monoclonal antibodies (daratumu- mab, elotuzumab), among others, which will hopefully further improve MM ... See full document

8

Bortezomib in the management of multiple myeloma

Bortezomib in the management of multiple myeloma

... Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone ... See full document

11

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update

... in multiple myeloma (MM) therapy with the introduction of several small molecules, mostly orally effective, whose mechanisms are based on proteasome inhibition, histone deacetylase (HDAC) blockade, and ... See full document

47

Spotlight on ixazomib: potential in the treatment of multiple myeloma

Spotlight on ixazomib: potential in the treatment of multiple myeloma

... dexamethasone treatment, out of which, 17 patients were placed on the secondary therapy for not achieving a response with ixazomib alone and five patients were placed on the secondary therapy for progression of ... See full document

10

Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis

Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis

... While the in vitro culture of plasmablasts provides a direct means for evaluating expressed Ig, the approach provides a very limited amount of material on which to perform tests. As a means to both pro- duce an ... See full document

14

Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens

Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens

... lymphocytic leukemia (8–11). Malignant transformation may occur directly via B cell infection and transformation, or indirectly via chronic Ag-driven stimulation of the B cell receptor (BCR) that has identical heavy and ... See full document

19

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth

... of myeloma tumors showed that delivery of BDA-366 into the mice significantly inhibited both RPMI8226 (Figure 6B) and U266 (Figure 6C) myeloma cell growth in ...DMSO treatment had no effect on the ... See full document

11

Bortezomib for the treatment of multiple myeloma

Bortezomib for the treatment of multiple myeloma

... some myeloma patients are unable to complete bortezomib treatment due to adverse events, such as nausea, fatigue, diarrhoea, peripheral neuropathy and thrombocy- topenia (Kyle ...combination ... See full document

13

Primary Bioassay of Human Myeloma Stem Cells

Primary Bioassay of Human Myeloma Stem Cells

... human monoclonal plasma cells in soft ...with multiple myeloma or related monoclonal disorders ...of myeloma colonies was proportional to the number of cells plated between ... See full document

10

Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues.

Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues.

... Reactivity of monoclonal antiviral antibodies with normal mouse tissues Reactivity with normal mouse tissueb Monoclonal antiviral antibody Immunoglobulin class Reactivity with viruSa Pit[r] ... See full document

5

Repurposing Dichloroacetate for the Treatment of  Multiple Myeloma

Repurposing Dichloroacetate for the Treatment of Multiple Myeloma

... DCA treatment, but PDK3 siRNA knockdown led to considerably increased sensitivity to DCA ...DCA treatment (Figure ...DCA treatment is displayed in Table ... See full document

237

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

... SMM is defined by serum M-protein (IgG or IgA) levels of ≥ 3 g/dL and/or clonal BMPCs of 10%–60% in the absence of myeloma defining events (MDEs) or amyloidosis. The updated IMWG diagnostic criteria for MM (Table ... See full document

11

In vivo effects of IgA and IgG2a anti CD3 isotype switch variants

In vivo effects of IgA and IgG2a anti CD3 isotype switch variants

... the first administration of OKT3, a murine anti-CD3 monoclonal antibody (mAb) of the IgG2a class, are largely attributed to the release of cytokines as a result of T cell activation caused by ... See full document

8

Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report

Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report

... his first kidney biopsy but before his diagnosis of MM, this patient received methyl-prednisolone pulse therapy for 2 ...the first BD course, labora- tory test results improved remarkably, with serum albu- ... See full document

6

Show all 10000 documents...